Premium
Immunotherapy with antibodies to the EGF receptor
Author(s) -
Dean C.,
Modjtahedi H.,
Eccles S.,
Box G.,
Styles J.
Publication year - 1994
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910570722
Subject(s) - immunotherapy , antibody , receptor , immunology , medicine , biology , immune system
A series of rat monoclonal antibodies (MAbs) has been generated against the extracellular domain of the receptor for EGF which block the binding of GF and TGFα to the receptor and inhibit the growth in vitro of a range of carcinoma cell lines that over‐express the receptor for EGF. Some of these antibodies were able also to induce the complete regression of xeno‐grafts of EGFR‐over‐expressing tumours when treatment was started, either at the time of tumour inoculation or later when the tumours were established. The most effective of these antibodies was ICR62, which was also able to activate host immune effector functions. We conclude that antibodies which block growth‐factor‐ligand interaction can have a profound influence on the proliferative capacity of tumour cells in vivo and may have useful clinical application.